TOP TEN perturbations for 40032_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40032_at
Selected probe(set): 205284_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40032_at (205284_at) across 6674 perturbations tested by GENEVESTIGATOR:

epigallocatechin gallate study 1 (45840ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):-3.0042439
Number of Samples:3 / 17
Experimental epigallocatechin gallate study 1 (45840ng/ml)
Bronchial epithelial cells (NHBE) treated with epigallocatechin gallate (45840ng/ml; vendor: Santa Cruz / catalog number: sc-200802 / catalog name: (-)-Epigallocatechin Gallate) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.6839647
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):2.3457603
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.333952
Number of Samples:4 / 4
Experimental R547 study 3 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):2.2727518
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):2.1858387
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.1388197
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):2.108533
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.1029415
Number of Samples:4 / 4
Experimental R547 study 1 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

CH5183284 study 1 (HSC-39) / vehicle (DMSO) treated HSC-39 cell sample

Relative Expression (log2-ratio):-2.1017494
Number of Samples:2 / 2
Experimental CH5183284 study 1 (HSC-39)
Human gastric cell line HSC-39 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated HSC-39 cell sample
Human gastric cell line HSC-39 treated with 0.1% DMSO for 24 hours.